ARS Pharmaceuticals, Inc.
NASDAQ:SPRYBiotechnology
-$0.35 today
- Market cap
- $370.95M
- Beta
- 0.83
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.99
Volume 1.70M
Average 1.67M
SPRY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
ARS Pharmaceuticals, Inc.NASDAQ: SPRY
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $159K fell 78.1% year over year, behind the +42.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 85.9% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.
Context
- Financing cash flow amounted to 124.1% of revenue in FY2025, up 42.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -78.1% toward the trailing-twelve-month pace of +42.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 104.6M USD
- Year-over-year change
- +44.5%
- 4-year CAGR
- +18.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.6M | +44.5% |
| FY2024 | 2024-12-31 | 72.4M | +949.4% |
| FY2023 | 2023-12-31 | 6.9M | -96.4% |
| FY2022 | 2022-12-31 | 190.73M | +258.8% |
| FY2021 | 2021-12-31 | 53.16M | — |
Financing Cash Flow vs competitors
How SPRY compares with its peers on the latest reported figures
- SPRY's LTM Mar 2026 financing cash flow of $104.03M is the 2nd largest of the 4 companies compared; the peer median is $86.39M.
- Its year-over-year change of +42.8% is the lowest of 4, against a peer median of +310.5%.
- Financing cash flow amounts to 105.1% of revenue for SPRY, versus a peer median of 77.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $278.74M | +310.5% | +145.1% | 77.3% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $104.03M | +42.8% | -18.1% | 105.1% |
| LTM Mar 2026 | $86.39M | +284.0% | +107.0% | 171.9% | |
| LTM Mar 2026 | $5.69M | +363.0% | -55.3% | 1.8% | |
| Peer median (excluding SPRY) | $86.39M | +310.5% | +107.0% | 77.3% | |
Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.24M) | (34.68M) | (54.37M) | 8M | (171.3M) |
| Depreciation & Amortization | 213K | 319K | 73K | (7.18M) | 1.37M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.83M | 5.84M | 9.24M | 14.53M | 22.1M |
| Change in Working Capital | (356K) | (12.75M) | (7.33M) | (1.81M) | (20M) |
| Accounts Receivables | 0 | 0 | 0 | (8.18M) | (17.21M) |
| Inventory | 0 | 0 | 0 | (5.95M) | (21.99M) |
| Accounts Payables | 0 | (10.29M) | (2.78M) | 16.43M | 18.88M |
| Other Working Capital | (356K) | (2.47M) | (4.55M) | (4.12M) | 306K |
| Other Non-Cash Items | (4K) | 1.2M | (6.88M) | 0 | (3.03M) |
| Operating Cash Flow | (17.56M) | (40.08M) | (59.27M) | 13.55M | (170.87M) |
| Capital Expenditures | (55K) | (199K) | (175K) | (563K) | (339K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (272.01M) | (356.04M) | (242.03M) |
| Sales of Investments | 0 | 0 | 185M | 258M | 307M |
| Other Investing Activities | 0 | 0 | 0 | (7.5M) | (7.86M) |
| Investing Cash Flow | (55K) | (199K) | (87.18M) | (106.1M) | 56.77M |
| Debt Repayment | (1.82M) | (8.68M) | 0 | 69.38M | 96.26M |
| Common Stock Issued | 169K | 570K | 6.9M | 3.02M | 5.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 198.84M | 0 | 0 | 2.66M |
| Financing Cash Flow | 53.16M | 190.73M | 6.9M | 72.4M | 104.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.54M | 150.46M | (139.55M) | (20.15M) | (9.5M) |
| Free Cash Flow | (17.62M) | (40.28M) | (59.44M) | 12.99M | (171.21M) |
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.